New results from the SirPAD randomized trial will be presented at VIVA 2026, October 3–6 at Bellagio Las Vegas, focusing on patients with femoropopliteal peripheral artery disease causing intermittent claudication. LAS VEGAS, Sept. 21, 2026 /PRNewswire/ -- SirPAD randomized 1,252 patients...
Hence then, the article about sirpad subgroup study at viva 2026 focuses on femoropopliteal pad in patients with claudication was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( SirPAD Subgroup Study at VIVA 2026 Focuses on Femoropopliteal PAD in Patients With Claudication )
Also on site :
- Placer County deputies search for man who fired shots at law enforcement, rammed patrol car
- Sweet Magnolias Stars And Creator Say Goodbye To Canceled Netflix Drama: 'I Hope Serenity Will Always Have A Place In Your Heart'
- 01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity